NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance
This article was originally published in The Pink Sheet Daily
Executive Summary
The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.